- Home
- MRKR vs AVAT Comparison
MRKR vs AVAT Comparison
Compare MRKR & AVAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRKR | AVAT |
|---|---|---|
| Founded | 1999 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 21.3M |
| IPO Year | 2010 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MRKR | AVAT |
|---|---|---|
| Price | $1.00 | $0.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.87 | N/A |
| AVG Volume (30 Days) | 168.4K | ★ 553.0K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.61 | N/A |
| Revenue Next Year | $375.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $0.29 |
| 52 Week High | $2.46 | $2.58 |
Technical Indicators
Market Signals| Indicator | MRKR | AVAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 39.68 |
| Support Level | $0.88 | $0.79 |
| Resistance Level | $1.32 | $1.41 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 31.33 | 12.46 |
Price Performance
Historical ComparisonAbout MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
About AVAT Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp is a digital asset treasury company.